Compare SLNG & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | CGTX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.2M | 110.8M |
| IPO Year | 2019 | 2021 |
| Metric | SLNG | CGTX |
|---|---|---|
| Price | $3.72 | $1.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $10.00 | $3.33 |
| AVG Volume (30 Days) | 19.5K | ★ 765.5K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2400.00 | 62.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,245,000.00 | N/A |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $14.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.21 | $0.24 |
| 52 Week High | $6.36 | $3.83 |
| Indicator | SLNG | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 50.33 |
| Support Level | $3.28 | $1.02 |
| Resistance Level | $3.83 | $1.19 |
| Average True Range (ATR) | 0.28 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 42.22 | 54.00 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).